326. Osteopetrosis Clinical trials / Disease details
Clinical trials : 20 / Drugs : 51 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 81
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00775931 (ClinicalTrials.gov) | August 2008 | 16/10/2008 | Allogeneic Transplantation For Severe Osteopetrosis | Allogeneic Hematopoietic Stem Cell Transplantation For Severe Osteopetrosis | Severe Osteopetrosis | Procedure: umbilical cord blood transplantation;Drug: Campath-1H;Radiation: Total Lymphoid Irradiation;Drug: Cyclophosphamide;Drug: Busulfan;Drug: Fludarabine monophosphate;Procedure: marrow graft transplantation | Masonic Cancer Center, University of Minnesota | NULL | Completed | N/A | 45 Years | All | 7 | Phase 2/Phase 3 | United States |
| 2 | NCT00638820 (ClinicalTrials.gov) | September 2007 | 11/3/2008 | Reduced Intensity AlloTransplant For Osteopetrosis | Reduced Intensity Allogeneic Transplantation For Severe Osteopetrosis Incorporating A Second Cd34 Selected Graft | Osteopetrosis | Procedure: Stem Cell or Umbilical Cord Blood Transplantation;Drug: Campath, Busulfan, Clofarabine;Procedure: Total Lymphoid Irradiation | Masonic Cancer Center, University of Minnesota | NULL | Terminated | N/A | 45 Years | All | 3 | Phase 2 | United States |